Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1995 Nov;73(5):427–430. doi: 10.1136/adc.73.5.427

Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial.

I M Bowler 1, B Kelman 1, D Worthington 1, J M Littlewood 1, A Watson 1, S P Conway 1, S W Smye 1, S L James 1, T A Sheldon 1
PMCID: PMC1511379  PMID: 8554360

Abstract

OBJECTIVE--To assess the benefit of nebulised amiloride added to the standard inpatient treatment of a respiratory exacerbation in cystic fibrosis. DESIGN--Prospective, randomised, double blind, placebo controlled trial. SUBJECTS--27 cystic fibrosis patients (mean age 12.8 years). SETTING--Two hospitals in Leeds, UK. RESULTS--Both forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) showed improvements over the course of treatment, although there was no difference in respiratory function between the two groups at any of three time periods during the study. The time to reach peak FVC was significantly reduced in the amiloride group (4.2 v 7.6 days; 95% CI 0.4 to 6.4 days), but not in the time to reach peak FEV1 (5.7 v 7.9 days; 95% CI -1.2 to 5.6 days). CONCLUSIONS--Amiloride did not result in a greater overall improvement in respiratory function. There was a suggestion that it may have an effect on the rate of improvement, and thus may possibly influence the duration of treatment. This hypothesis deserves further evaluation.

Full text

PDF
427

Images in this article

428p428-a
on p.428

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. App E. M., King M., Helfesrieder R., Köhler D., Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis. 1990 Mar;141(3):605–612. doi: 10.1164/ajrccm/141.3.605. [DOI] [PubMed] [Google Scholar]
  2. Boucher R. C., Cotton C. U., Gatzy J. T., Knowles M. R., Yankaskas J. R. Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol. 1988 Nov;405:77–103. doi: 10.1113/jphysiol.1988.sp017322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boucher R. C., Stutts M. J., Knowles M. R., Cantley L., Gatzy J. T. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest. 1986 Nov;78(5):1245–1252. doi: 10.1172/JCI112708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohn R. C., Jacobs M., Aronoff S. C. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 1988 Mar;32(3):395–396. doi: 10.1128/aac.32.3.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohn R. C., Rudzienski L., Putnam R. W. In vitro antimicrobial activity of amiloride analogs against Pseudomonas. Chemotherapy. 1992;38(4):232–237. doi: 10.1159/000239006. [DOI] [PubMed] [Google Scholar]
  6. Conway S. P., Miller M. G., Ramsden C., Littlewood J. M. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatr Scand. 1985 Jan;74(1):107–113. doi: 10.1111/j.1651-2227.1985.tb10929.x. [DOI] [PubMed] [Google Scholar]
  7. Graham A., Hasani A., Alton E. W., Martin G. P., Marriott C., Hodson M. E., Clarke S. W., Geddes D. M. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J. 1993 Oct;6(9):1243–1248. [PubMed] [Google Scholar]
  8. Knowles M. R., Church N. L., Waltner W. E., Yankaskas J. R., Gilligan P., King M., Edwards L. J., Helms R. W., Boucher R. C. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 1990 Apr 26;322(17):1189–1194. doi: 10.1056/NEJM199004263221704. [DOI] [PubMed] [Google Scholar]
  9. Knowles M. R., Clarke L. L., Boucher R. C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med. 1991 Aug 22;325(8):533–538. doi: 10.1056/NEJM199108223250802. [DOI] [PubMed] [Google Scholar]
  10. Knowles M., Gatzy J., Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981 Dec 17;305(25):1489–1495. doi: 10.1056/NEJM198112173052502. [DOI] [PubMed] [Google Scholar]
  11. Köhler D., App E., Schmitz-Schumann M., Würtemberger G., Matthys H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl. 1986;146:319–326. [PubMed] [Google Scholar]
  12. Lindemann H., Becker T., Bittner P., Boldt A., Hofmann T., Schwandt H. J. Sekretelimination bei CF-Patienten unter Amiloridinhalation. Pneumologie. 1990 Oct;44(10):1148–1150. [PubMed] [Google Scholar]
  13. Matthews J. N., Altman D. G., Campbell M. J., Royston P. Analysis of serial measurements in medical research. BMJ. 1990 Jan 27;300(6719):230–235. doi: 10.1136/bmj.300.6719.230. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES